#USA #Deerfield #Hemopatch #Baxter International #hemostatic sealant

Introducing HEMOPATCH: A Breakthrough in Hemostasis

Baxter International has announced the launch of HEMOPATCH, a unique hemostatic sealant that stands out in the healthcare market as it can be stored at room temperature. This innovative product is designed for effective hemostasis and closure of wounds in both open and minimally invasive surgical procedures. Steve Wallace, the president of Baxter's Advanced Surgery division, emphasizes the significance of this new offering, which underscores the company’s commitment to delivering advanced tissue management solutions.

Key Features and Benefits

HEMOPATCH is particularly distinguished by its extended shelf life of three years, making it a practical option for healthcare providers who seek to improve their clinical practices. The hemostatic patch operates through the interaction of two essential components, which facilitates rapid and effective hemostasis by sealing bleeding surfaces effectively. The white side of the patch, which adheres to the tissue, is coated with a thin layer of NHS-PEG. Upon contact with blood or other bodily fluids, this layer forms a hydrogel that enhances adhesion and seals the tissue surface.

When in contact with blood, the collagen component triggers the aggregation of platelets. This leads to a significant increase in the number of platelets accumulating on the collagen structure, resulting in degranulation and the release of coagulation factors. These factors, along with plasma proteins, contribute to the formation of fibrin, which is critical for proper clot formation.

Moreover, the three-dimensional structure of HEMOPATCH is designed to absorb fluids effectively while providing additional mechanical reinforcement to the blood clot. Preclinical studies suggest that absorption and replacement by host tissue occurs approximately within six to eight weeks with minimal tissue reaction. However, this process may vary based on several factors, including the quantity of the product left in situ and the site of application.

Clinical Advantages

HEMOPATCH is clinically advantageous for its multiple applications, including tissue sealing, bleeding control, and rapid hemostasis achievable within just two minutes. The hemostatic patch is designed to not only stop bleeding but also prevent any seepage, thereby ensuring optimal conditions for surgical recovery. Its application is not limited to conventional surgeries; it is equally effective in minimally invasive procedures, marking a versatile tool for surgeons.

The introduction of HEMOPATCH reflects the progressive strides Baxter has made in surgery, particularly in hemostatic management. The product is being tailored for specific regulatory approvals across various countries, ensuring compliance with local medical standards. Baxter encourages healthcare professionals to reach out for insights about product availability and regulatory status in their respective regions.

Conclusion

As an innovative solution in surgical hemostasis, HEMOPATCH promises to redefine standards in wound management. For more detailed information, including indications and important risk information, healthcare providers can visit the dedicated product page on Baxter's website or watch informational videos that discuss its benefits and usage extensively. As Baxter continues to lead in the healthcare industry, products like HEMOPATCH exemplify their dedication to advancing medical technology with a focus on patient safety and treatment efficacy.

For those interested in exploring HEMOPATCH and its application in surgical settings, it's essential to stay informed about the latest advancements through reliable sources and Baxter's official communications.